Eli Lilly 2007 Annual Report Download - page 15

FINANCIALS
13
The following table summarizes our net sales activity in 2007 compared with 2006:
Year Ended Year Ended Percent
December 31, 2007 December 31, 2006 Change
Product U.S.1 Outside U.S. Total Total from 2006
(Dollars in millions)
Zyprexa . . . . . . . . . . . . . . . . . . . . . . . $ 2,236.0 $2,525.0 $ 4,761.0 $ 4,363.6 9
Cymbalta . . . . . . . . . . . . . . . . . . . . . 1,835.6 267.3 2,102.9 1,316.4 60
Gemzar . . . . . . . . . . . . . . . . . . . . . . . 670.0 922.4 1,592.4 1,408.1 13
Humalog . . . . . . . . . . . . . . . . . . . . . . 888.0 586.6 1,474.6 1,299.5 13
Cialis2 . . . . . . . . . . . . . . . . . . . . . . . . 423.8 720.0 1,143.8 215.8 NM
Evista . . . . . . . . . . . . . . . . . . . . . . . . 706.1 384.6 1,090.7 1,045.3 4
Animal health products . . . . . . . . . 480.9 514.9 995.8 875.5 14
Humulin® . . . . . . . . . . . . . . . . . . . . . 365.2 620.0 985.2 925.3 6
Alimta . . . . . . . . . . . . . . . . . . . . . . . . 448.0 406.0 854.0 611.8 40
Forteo® . . . . . . . . . . . . . . . . . . . . . . 494.1 215.2 709.3 594.3 19
Strattera® . . . . . . . . . . . . . . . . . . . . 464.6 104.8 569.4 579.0 (2)
Humatrope® . . . . . . . . . . . . . . . . . . 213.6 227.2 440.8 415.6 6
Actos® . . . . . . . . . . . . . . . . . . . . . . . 150.8 219.8 370.6 448.5 (17)
Byetta . . . . . . . . . . . . . . . . . . . . . . . . 316.5 14.2 330.7 219.0 51
Other pharmaceutical products . . 452.3 760.0 1,212.3 1,373.3 (12)
Total net sales . . . . . . . . . . . . . . $10,145.5 $8,488.0 $18,633.5 $15,691.0 19
NM—Not meaningful
1U.S. sales include sales in Puerto Rico.
2Prior to the acquisition of ICOS, the Cialis sales shown in the table above represent results only in the territories in which we marketed
Cialis exclusively. The remaining sales relate to the joint-venture territories of Lilly ICOS LLC (North America, excluding Puerto Rico,
and Europe). Our share of the joint-venture territory sales, net of expenses and income taxes, is reported in other income—net in our
consolidated income statement. Subsequent to the acquisition, all Cialis product sales are reported in our net sales.
tile dysfunction, were $1.22 billion and $971.0 million
during 2007 and 2006, respectively. This includes $72.7
million of sales in the Lilly ICOS joint-venture territo-
ries for the 2007 period prior to the acquisition of ICOS.
Worldwide sales grew 25 percent in 2007. U.S. sales in-
creased 20 percent in 2007, driven by increased demand
and higher prices. Sales outside the U.S. increased 28
percent in 2007, driven by increased demand, the favor-
able impact of foreign exchange rates, and higher prices.
Prior to the ICOS acquisition, Cialis sales in our terri-
tories were reported in net sales, while our 50 percent
share of the joint-venture net income was reported in
other income—net. All sales of Cialis subsequent to the
ICOS acquisition are reported in our net sales.
Sales of Evista, a product for the prevention and
treatment of osteoporosis in postmenopausal women
and for risk reduction of invasive breast cancer in post-
menopausal women with osteoporosis and postmeno-
pausal women at high risk for invasive breast cancer,
increased 6 percent in the U.S., driven by higher prices.
Sales outside the U.S. increased 1 percent, driven by
the favorable impact of foreign exchange rates, partially
offset by lower prices and lower demand.
Sales of Humulin, an injectable human insulin for
the treatment of diabetes, decreased 1 percent in the
U.S., driven by lower demand, partially offset by higher
prices. Sales outside the U.S. increased 11 percent,
driven by increased demand and the favorable impact of
foreign exchange rates, partially offset by lower prices.
Sales of Alimta, a second-line treatment for non-
small cell lung cancer and in combination with another
agent, for the treatment of malignant pleural meso-
thelioma, increased 28 percent in the U.S., driven by
increased demand and to a lesser extent, higher prices.
Sales outside the U.S. increased 55 percent, driven by
increased demand and to a lesser extent, the favorable
impact of foreign exchange rates.
Sales of Forteo, an injectable treatment for osteo-
porosis in postmenopausal women and men at high risk
for fracture, increased 19 percent in the U.S., driven by
higher net selling prices. U.S. sales growth benefi ted
from access to medical coverage through the Medi-
care Part D program and decreased utilization of our
U.S. patient assistance program and to a lesser extent,
increased demand. Sales outside the U.S. increased 21
percent, driven by increased demand and the favorable
impact of foreign exchange rates.
Sales of Strattera, a treatment for attention-defi cit
hyperactivity disorder in children, adolescents, and
adults, decreased 9 percent in the U.S., as a result of
decreased demand. Sales outside the U.S. increased
50 percent, driven by increased demand and the favor-
able impact of foreign exchange rates.
Our revenues from Actos, an oral agent for the